Oral contraceptives influence plasma proteins, causing changes in plasma procoagulants
and fibrinolytic effectors. Estrogen is thought to be responsible for these changes, whereas …

Evidence is provided that the fibrinolytic capacity in plasma is strongly dependent on
circulating concentrations of tissue plasminogen activator rather than on concentrations of …

In Europe and North America, estrogen/progestogen oral contraception has been
associated with an increase in venous thromboembolism, myocardial infarction, and stroke …

Objective To determine the effect of oestrogen dose and progestogen type on the
coagulation and fibrinolytic systems of a group of normal healthy women taking three …

Three oral contraceptive preparations were compared for effects on blood coagulation,
fibrinolysis and platelet function in a total of 86 healthy young women. Two of the …

A prospective investigation was initiated to assess the effect of a low-dose oral contraceptive
containing 35 μg of ethinyl estradiol and 0.4 mg of norethindrone on blood coagulation and …

Oral contraceptives have been linked to an increased incidence of thrombovascular
disease. This may be mediated by their effects on the haemostatic system. An increase in …

Epidemiologic data support the notion that first-generation high-dose oral contraceptives
(containing> 80 μg of estrogen) increased the incidence of thromboembolic events. The …

PIP: The association between thrombosis and use of oral contraceptives has been
confirmed again and again by epidemiologic data. However, what remains to be …

The hemostatic effects of a new triphasic oral contraceptive combination containing
ethinylestradiol and the new progestogen gestodene were compared with those of a …